Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors

[1]  J. Slattery,et al.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.

[2]  S. Grundy,et al.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholeserolemia heterozygotes. 1983. , 1983, Atherosclerosis. Supplements.

[3]  H. Mabuchi,et al.  Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981. , 1981, Atherosclerosis. Supplements.

[4]  R. Collins,et al.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial , 2003, The Lancet.

[5]  W. März,et al.  Risk for myopathy with statin therapy in high-risk patients. , 2003, Archives of internal medicine.

[6]  T. Lancet.  How a statin might destroy a drug company , 2003, The Lancet.

[7]  E. Bruckert.  New lipid-modifying therapies , 2003, Expert opinion on investigational drugs.

[8]  P. Neuvonen,et al.  Gemfibrozil greatly increases plasma concentrations of cerivastatin , 2002, Clinical pharmacology and therapeutics.

[9]  P. Serruys,et al.  Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention , 2002 .

[10]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[11]  S. Yusuf.  Two decades of progress in preventing vascular disease , 2002, The Lancet.

[12]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[13]  K. Tolman.  The liver and lovastatin. , 2002, The American journal of cardiology.

[14]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[15]  S. Hampson.  Randomised, placebo-controlled trial , 2002 .

[16]  J. Larosa,et al.  Pleiotropic effects of statins and their clinical significance. , 2001, The American journal of cardiology.

[17]  R. Collins,et al.  Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials , 2001, The Lancet.

[18]  M. H. Davidson.  Statin trials in progress: Unanswered questions , 2001, Current atherosclerosis reports.

[19]  Jiang He,et al.  Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials , 2000 .

[20]  A. Yeung,et al.  Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. , 2000, Circulation.

[21]  A. Clayton,et al.  A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[22]  G. Thorgeirsson,et al.  Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. , 2000, The American journal of cardiology.

[23]  HOMAS,et al.  The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels , 2000 .

[24]  Ames,et al.  PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA , 2000 .

[25]  J. Larosa,et al.  Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. , 1999, JAMA.

[26]  A. Gotto,et al.  Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. , 1999, JAMA.

[27]  M. Mercuri,et al.  Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. , 1999, The American journal of cardiology.

[28]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[29]  E. Stein.  Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. , 1998, The American journal of cardiology.

[30]  A. Gotto,et al.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. , 1998, JAMA.

[31]  T. Lancaster,et al.  The new NHS: Medical students say no , 1998 .

[32]  Y. Chao,et al.  Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. , 1998, Biochimica et biophysica acta.

[33]  D. Illingworth,et al.  Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. , 1997, Atherosclerosis.

[34]  Clare,et al.  Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. , 1997, Journal of lipid research.

[35]  Y. Chao,et al.  27 Hepatic responses to inhibition of HMG-CoA reductase: a comparison of atorvastatin and simvastatin , 1997 .

[36]  G. Thorgeirsson,et al.  Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. , 1996, Archives of internal medicine.

[37]  R. Collins,et al.  Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration , 1996, BMJ.

[38]  G. Taylor,et al.  Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. , 1996, Atherosclerosis.

[39]  W. Kannel,et al.  Clinical misconceptions dispelled by epidemiological research. , 1995, Circulation.

[40]  R. Collins,et al.  Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. , 1995, The British journal of ophthalmology.

[41]  S. Ellis,et al.  Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. , 1995, Journal of the American College of Cardiology.

[42]  J. Salonen,et al.  Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. , 1995, Circulation.

[43]  P. Poole‐Wilson,et al.  Lower patients' cholesterol now , 1995, BMJ.

[44]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[45]  Gram Jb,et al.  The Scandinavian Simvastatin Survival Study (4S) , 1995 .

[46]  F. Gengo,et al.  Effects of treatment with lovastatin and pravastatin on daytime cognitive performance , 1995, Clinical cardiology.

[47]  J. Gram.  [The Scandinavian Simvastatin Survival Study (4S)]. , 1995, Ugeskrift for laeger.

[48]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[49]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice , 1994 .

[50]  Alan C. Wilson,et al.  Central Nervous System Effects of HMG CoA Reductase Inhibitors: Lovastatin and Pravastatin on Sleep and Cognitive Performance in Patients with Hypercholesterolemia , 1994, Journal of clinical pharmacology.

[51]  P. Poole‐Wilson,et al.  Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. , 1994, European heart journal.

[52]  C. Furberg,et al.  Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. , 1994, Circulation.

[53]  M-heart investigators.  Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[54]  T. Strandberg,et al.  Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. , 1994, The American journal of cardiology.

[55]  C. Ashton,et al.  Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. , 1994, British journal of clinical pharmacology.

[56]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[57]  K. von Bergmann,et al.  Ocular drug safety and HMG-CoA-reductase inhibitors. , 1994, Ophthalmic research.

[58]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[59]  L. Chylack,et al.  Lovastatin and the human lens; results of a two year study. The MSDRL Study Group. , 1993, Optometry and vision science : official publication of the American Academy of Optometry.

[60]  Y. Adler,et al.  Gemfibrozil-induced myopathy , 1993, Harefuah.

[61]  J. Mckenney,et al.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) , 1993, JAMA.

[62]  G. Block,et al.  The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. , 1993, British journal of clinical pharmacology.

[63]  R. Collins.  CHOLESTEROL LOWERING TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT , 1993 .

[64]  M. Oliver.  Is cholesterol reduction always safe? , 1992, European journal of clinical investigation.

[65]  Y. Arad,et al.  Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. , 1992, Metabolism: clinical and experimental.

[66]  G. Davey Smith,et al.  Should there be a moratorium on the use of cholesterol lowering drugs? , 1992, BMJ.

[67]  S. Grossman,et al.  HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. , 1991, The Journal of pharmacology and experimental therapeutics.

[68]  H. Taylor,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. , 1991, The American journal of cardiology.

[69]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.

[70]  H. Taylor,et al.  The human lens after 48 weeks of treatment with lovastatin. , 1990, The New England journal of medicine.

[71]  K. Matthews,et al.  Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. , 1990, BMJ.

[72]  K. Einarsson,et al.  Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. , 1990, The New England journal of medicine.

[73]  T. Gross,et al.  Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. , 1990, JAMA.

[74]  D. Hunninghake,et al.  A muclticenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia , 1990 .

[75]  O. Hockwin,et al.  No lens changes caused by simvastatin results from a prospective drug safety study. , 1990, Lens and eye toxicity research.

[76]  D. Kornbrust,et al.  Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. , 1989, The American journal of medicine.

[77]  D. Steinberg,et al.  The cholesterol controversy is over. Why did it take so long? , 1989, Circulation.

[78]  D. Illingworth,et al.  Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. , 1989, The Journal of laboratory and clinical medicine.

[79]  I. Singer,et al.  Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[80]  D. Illingworth,et al.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. , 1988, The New England journal of medicine.

[81]  R. Lees,et al.  Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. , 1987, Annals of internal medicine.

[82]  T. Südhof,et al.  Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[83]  J. Ford,et al.  Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia. , 1986, The Quarterly journal of medicine.

[84]  M. Brown,et al.  A receptor-mediated pathway for cholesterol homeostasis. , 1986, Science.

[85]  J. Hupp.  Lowering Blood Cholesterol to Prevent Heart Disease , 1985, International Journal of Technology Assessment in Health Care.

[86]  L. Wilkins.  Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement. , 1985, Nutrition reviews.

[87]  R. Collins,et al.  CHOLESTEROL-LOWERING TRIAL RESULTS IN THEIR EPIDEMIOLOGIC CONTEXT , 1985 .

[88]  P. Edwards,et al.  The regulation of acetoacetyl-CoA synthetase activity by modulators of cholesterol synthesis in vivo and the utilization of acetoacetate for cholesterogenesis. , 1984, The Journal of biological chemistry.

[89]  D. Illingworth,et al.  Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. , 1984, The Journal of clinical investigation.

[90]  C. E. Becker.  The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. , 1984, JAMA.

[91]  H. Blackburn,et al.  The seven countries study: 2,289 deaths in 15 years. , 1984, Preventive medicine.

[92]  S M Grundy,et al.  Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[93]  H. Mabuchi,et al.  Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. , 1983, The New England journal of medicine.

[94]  Y. Chao,et al.  Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers. , 1982, The Journal of clinical investigation.

[95]  G. Hitzenberger,et al.  Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. , 1982, Atherosclerosis.

[96]  M. Oliver.  SERUM CHOLESTEROL-THE KNAVE OF HEARTS AND THE JOKER , 1981, The Lancet.

[97]  D. Bilheimer,et al.  Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Y. Tsujita,et al.  Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia. , 1981, Atherosclerosis.

[99]  H. Mabuchi,et al.  Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. , 1981, The New England journal of medicine.

[100]  R Monaghan,et al.  Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[101]  M. Brown,et al.  Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. , 1980, Journal of lipid research.

[102]  R. Fears,et al.  The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. , 1980, Atherosclerosis.

[103]  Y. Tsujita,et al.  Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. , 1979, Atherosclerosis.

[104]  Y. Tsujita,et al.  Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1977, European journal of biochemistry.

[105]  M. Brown,et al.  Regulation of cholesterol synthesis in rat adrenal gland through coordinate control of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase activities. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[106]  Y. Tsujita,et al.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. , 1976, The Journal of antibiotics.

[107]  J. Fahey,et al.  Letter: Toxicity of intravenous Corynebacterium parvum. , 1975, Lancet.

[108]  J. Stamler.  Clofibrate and niacin in coronary heart disease. , 1975, JAMA.

[109]  Kirby Tj.  Cataracts produced by triparanol. (MER-29). , 1967 .

[110]  T. Kirby.  Cataracts produced by triparanol. (MER-29). , 1967, Transactions of the American Ophthalmological Society.